Source: GlobalNewswire

Press Release: Axsome : Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer's Disease Agitation Supporting NDA Submission

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025

Read full article »
Axsome's Competitors | Axsome's News | Axsome's Financials
Stay up-to-date with the latest news on Axsome
Annual Revenue
$100-500M
Employees
500-1.0K
Herriot Tabuteau's photo - Chairman & CEO of Axsome

Chairman & CEO

Herriot Tabuteau

CEO Approval Rating

89/100

Read more
Stay up-to-date with the latest news on Axsome